On The Fly
| ShowHide Related Items >><< - 05/22/22
- Fly Intel: Top five weekend stock stories
- 05/16/22
- Warby Parker reports active customers increased 18.0% to 2.23M in Q1
- 03/17/22
- Warby Parker drops 12% to $23.60 after FY22 revenue guidance misses estimates
- 03/11/22
- Warby Parker announces new partnership with Eastman Chemical
SWTX SpringsWorks Therapeutics - 05/26/22
- SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO
- 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
RXRX Recursion Pharmaceuticals - 06/20/22
- Recursion announces initiation of Phase 2/3 trial for NF2-Mutated Meningiomas
- 04/11/22
- Recursion Pharmaceuticals granted FDA Fast Track designation for REC-4881
- 03/18/22
- Recursion Pharmaceuticals enrolls first patient in Phase 2 SYCAMORE trial
- 03/03/22
- Recursion provides updated guidance on clinical trial starts
- $200.01 /
+11.95 (+6.35%) - 06/15/22
- MicroStrategy up 8% to $170, off highs as CEO interview ends on CNBC
- 06/15/22
- MicroStrategy CEO says strategy is to be 'levered, long bitcoin'
- 06/15/22
- MicroStrategy CEO says excess cash will be used to buy more bitcoin
- 06/15/22
- MicroStrategy CEO says 98% of world doesn't understand digital scarcity concept
- 06/21/22
- Cronos Group, Ginkgo Bioworks announce achievement of THCV equity milestone
- 06/21/22
- Ginkgo Bioworks and Cronos Group achieve THCV productivity milestone
- 06/07/22
- Ginkgo Bioworks, Novo Nordisk to partner on expression systems
- 06/06/22
- Ginkgo Bioworks acquires certain assets from Bitome
- 05/17/22 Goldman Sachs
- Warby Parker downgraded to Neutral from Buy at Goldman Sachs
- 05/17/22 Baird
- Warby Parker price target lowered to $30 from $40 at Baird
- 05/17/22 Citi
- Warby Parker price target lowered to $29 from $41 at Citi
- 03/30/22 Stifel
- Warby Parker initiated with a Hold at Stifel
- 06/16/22 Jefferies
- Ginkgo Bioworks price target lowered to $4.35 from $11.50 at Jefferies
- 05/18/22 BofA
- BofA downgrades Ginkgo Bioworks to Underperform, halves target to $3
- 05/18/22 BofA
- Ginkgo Bioworks downgraded to Underperform from Neutral at BofA
- 03/31/22 BTIG
- Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
RXRX Recursion Pharmaceuticals - 04/18/22 BofA
- Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
- 03/04/22 SVB Securities
- Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
- 09/21/21 Berenberg
- Recursion Pharmaceuticals initiated with a Buy at Berenberg
- $200.01 /
+11.95 (+6.35%) - 06/16/22 Jefferies
- Jefferies cuts MicroStrategy target, says does not face solvency risk
- 06/14/22 BTIG
- MicroStrategy margin call concerns 'blown out of proportion,' says BTIG
- 05/23/22 Jefferies
- MicroStrategy price target lowered to $215 from $225 at Jefferies
- 05/16/22 Jefferies
- MicroStrategy does not face liquidity, solvency risk, says Jefferies
SWTX SpringsWorks Therapeutics - 06/06/22 H.C. Wainwright
- SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
- 06/06/22 H.C. Wainwright
- Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 05/27/22 Wedbush
- SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
- 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
- 05/16/22
- Warby Parker backs FY22 revenue view $650M-$660M, consensus $656.98M
- 05/16/22
- Warby Parker reports Q1 adjusted EPS (30c), consensus 1c
- 03/17/22
- Warby Parker sees 2022 revenue $650M-$660M, consensus $687.75M
- 03/17/22
- Warby Parker reports Q4 adjusted EPS (8c), consensus (9c)
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
RXRX Recursion Pharmaceuticals - 03/23/22
- Recursion Pharmaceuticals reports Q4 EPS (38c), consensus (31c)
- $200.01 /
+11.95 (+6.35%) - 05/03/22
- MicroStrategy reports Q1 adjusted EPS ($10.42), two estimates $1.41
- 02/01/22
- MicroStrategy reports Q4 EPS ($8.43), consensus $1.49
- 05/16/22
- Ginkgo Bioworks sees FY22 revenue view to $375M-$390M from $325M-$340M
- 05/16/22
- Ginkgo Bioworks reports Q1 revenue $168M, consensus $105.68M
- 03/28/22
- Ginkgo Bioworks sees FY22 revenue $325M-$340M, consensus $305.75M
- 03/28/22
- Ginkgo Bioworks reports Q4 EPS ($1.10), consensus (4c)
|
On The Fly
| ShowHide Related Items >><< TPTX Turning Point Therapeutics - 06/03/22
- Turning Point Therapeutics jumps 117% to $74.16 after Bristol-Myers buyout offer
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 05/16/22
- Turning Point Therapeutics appoints Steve Sabus as CCO
SWTX SpringsWorks Therapeutics - 05/26/22
- SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO
- 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
- 12/10/21
- SpringsWorks Therapeutics announces trial collaboration with AbbVie
- 05/04/22
- Spotify introduces 'Spotify Island' on Roblox
- 04/27/22
- Spotify falls -11.2%
- 04/27/22
- Spotify falls -8.7%
- 04/27/22
- Spotify: Guidance reflects full closure of services in Russia
- 02/28/22
- Semrush plans acquisition of Austin-based Kompyte, no terms
- 01/19/22
- Semrush acquires Backlinko.com, terms not disclosed
RVMD Revolution Medicines - 03/24/22
- Revolution Medicines director buys $5.49M in common stock
- 05/26/22
- PMV Pharmaceuticals: Lead program, PC14586 accepted as oral presentation at ASCO
- 04/27/22
- PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO
- 06/02/22
- Lululemon reports Q1 SSS up 28% or up 29% on constant FX
- 05/10/22
- Nielsen selected by Lululemon as Marketing Mix Modeling provider
- 04/21/22
- Xponential Fitness enters collaboration with Lululemon, MIRROR
- 04/20/22
- Lululemon announces five year growth plan to double revenue to $12.5B by 2026
- 06/06/22
- Carl Icahn to discontinue proxy contest waged at Kroger, withdraw nominees
- 05/25/22
- Kroger expands Fulfillment Network to Central Ohio
- 05/09/22
- Else Nutrition receives formal listing approval for cereals on Kroger.com
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- 05/10/22
- L.B. Foster sees funding operations in 2022 and beyond
- 03/01/22
- L.B. Foster maintains 'optimistic outlook' regarding long-term trends
- 12/09/21
- Edison International raises quarterly dividend to 70c per share
- 03/30/22
- Dun & Bradstreet to divest business-to-consumer marketing business in Germany
- 02/16/22
- Dun & Bradstreet announce 10-year strategic agreement
- 02/15/22
- Cannae Holdings sells 20% interest in Optimal Blue to Black Knight for $578M
- 01/13/22
- Dun & Bradstreet to make operational changes, refunds to settle FTC charges
- 05/20/22
- DoorDash discloses $400M share repurchase program
- 05/16/22
- Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe
- 05/12/22
- Instacart announces confidential submission of draft registration statement
- $164.16 /
+2.095 (+1.29%) - 05/16/22
- Tiger Global buys Starry, exits Adobe in Q1
- 04/08/22
- Crowdstrike targets over $5B in annual recurring revenue
- 04/07/22
- Crowdstrike announces IL-4 authorization to protect DOD assets
- 04/07/22
- Crowdstrike, Mandiant announce strategic partnership
- 06/06/22
- Bristol-Myers reports three-year data from Phase 3 CheckMate -9LA trial
- 06/06/22
- Bristol-Myers reports five-year data from Phase 3 CheckMate -227 trial
- 06/03/22
- Bristol-Myers withdraws sBLA for Reblozyl
- 06/06/22
- Bausch + Lomb announces seven presentations on Biotrue products
- 06/02/22
- Bausch + Lomb announces U.S. launch of Biotrue Hydration Plus Solution
- 05/24/22
- Bausch + Lomb receives Health Canada approval for Lumify
- 05/12/22
- Bausch + Lomb release survey findings on macular edema treatment
- 05/16/22
- Berkshire Hathaway adds Citi, exits Wells Fargo in Q1
- 05/10/22
- American Express partners with Versapay for accounts receivable experience
- 04/28/22
- American Express enters integration collaboration with Billtrust
- 04/13/22
- Bread Financial launches new consumer credit card
- 06/03/22
- Aurora Cannabis repurchases $20M of convertible senior notes
- 05/18/22
- Aurora Cannabis receives EU-GMP certification for facility in Germany
- 05/12/22
- Aurora Cannabis raises expense savings target to C$150M-C$170M
- 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 06/06/22 Raymond James
- Raymond James upgrades Spotify to buy with bad news priced in
- 06/06/22 Raymond James
- Spotify upgraded to Outperform from Market Perform at Raymond James
- 04/29/22 Citi
- Spotify price target lowered to $165 from $240 at Citi
- 04/28/22 Truist
- Spotify price target lowered to $150 from $210 at Truist
- $164.16 /
+2.095 (+1.29%) - 06/06/22 Morgan Stanley
- Crowdstrike upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/03/22 Morgan Stanley
- Crowdstrike price target raised to $195 from $181 at Morgan Stanley
- 06/03/22 Jefferies
- Crowdstrike price target raised to $215 from $200 at Jefferies
- 06/03/22 DA Davidson
- Crowdstrike price target lowered to $235 from $280 at DA Davidson
- 06/06/22 Barclays
- Lululemon price target lowered to $435 from $450 at Barclays
- 06/06/22 Bernstein
- Lululemon upgraded to Market Perform from Underperform at Bernstein
- 06/03/22 UBS
- Lululemon price target lowered to $365 from $430 at UBS
- 06/03/22 Morgan Stanley
- Lululemon Q1 results 'speak for themselves,' says Morgan Stanley
- 06/06/22 Raymond James
- DoorDash initiated with a Market Perform at Raymond James
- 06/03/22 DA Davidson
- DoorDash price target lowered to $82 from $135 at DA Davidson
- 06/02/22 JMP Securities
- DoorDash price target lowered to $150 from $200 at JMP Securities
- 06/02/22 Truist
- DoorDash price target lowered to $185 from $200 at Truist
- 06/06/22 Stifel
- Aurora Cannabis upgraded to Hold from Sell at Stifel
- 05/16/22 CIBC
- Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
- 05/13/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 06/06/22 Edward Jones
- American Express upgraded to Buy from Hold at Edward Jones
- 05/12/22 Wolfe Research
- Wolfe downgrades credit card issuers on 80% probability of recession
- 05/12/22 Wolfe Research
- American Express downgraded to Peer Perform from Outperform at Wolfe Research
- 04/26/22 Citi
- American Express price target raised to $190 from $187 at Citi
TPTX Turning Point Therapeutics - 06/06/22 Cowen
- Turning Point Therapeutics downgraded to Market Perform from Outperform at Cowen
- 06/06/22 H.C. Wainwright
- Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 06/05/22 BofA
- BofA keeps Buy on Bristol-Myers, raises price target to $80
- 06/03/22 Oppenheimer
- Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
- 06/03/22 Stifel
- Bristol-Myers' offer for Turning Point Therapeutics 'fair,' says Stifel
- 03/02/22 Oppenheimer
- Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
- 03/02/22 Oppenheimer
- PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- 09/22/21 Goldman Sachs
- PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
SWTX SpringsWorks Therapeutics - 06/06/22 H.C. Wainwright
- SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
- 05/27/22 Wedbush
- SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
- 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
RVMD Revolution Medicines - 05/20/22 BofA
- BofA starts Revolution Medicines at Neutral with $24 price target
- 05/20/22 BofA
- Revolution Medicines initiated with a Neutral at BofA
- 03/01/22 Stifel
- Stifel upgrades Revolution Medicines, sees good entry point after pullback
- 06/06/22 B. Riley
- L.B. Foster downgraded to Neutral on inflation headwinds at B. Riley
- 06/06/22 B. Riley
- L.B. Foster downgraded to Neutral from Buy at B. Riley
- 03/10/22 B. Riley
- L.B. Foster price target lowered to $18 from $21 at B. Riley
- 08/04/21 B. Riley
- L.B. Foster price target raised to $21 from $19 at B. Riley
- 06/06/22 UBS
- Edison International downgraded to Neutral from Buy at UBS
- 06/06/22 UBS
- Edison International downgraded to Neutral from Buy at UBS
- 05/10/22 Mizuho
- Edison International downgraded to Neutral from Buy at Mizuho
- 05/04/22 Citi
- Edison International price target raised to $79 from $67 at Citi
- 06/06/22 RBC Capital
- Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
- 06/06/22 RBC Capital
- Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
- 05/17/22 Barclays
- Dun & Bradstreet price target lowered to $18 from $22 at Barclays
- 05/10/22 Needham
- Dun & Bradstreet price target lowered to $21 from $28 at Needham
- 06/06/22 BofA
- GoodRx reinstated with a Buy at BofA
- 06/01/22 Baird
- Baird downgrades GoodRx to Neutral amid disruption at Kroger
- 06/01/22 Baird
- GoodRx downgraded to Neutral from Outperform at Baird
- 05/16/22 Baird
- Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
- 06/06/22 Guggenheim
- Kroger price target raised to $57 from $49 at Guggenheim
- 06/02/22 Deutsche Bank
- Kroger price target raised to $50 from $49 at Deutsche Bank
- 06/06/22 Citi
- Bausch + Lomb initiated with a Buy at Citi
- 05/31/22 Jefferies
- Bausch + Lomb initiated with a Buy at Jefferies
- 05/31/22 BofA
- Bausch + Lomb initiated with a Buy at BofA
- 05/31/22 Deutsche Bank
- Bausch + Lomb initiated with a Hold at Deutsche Bank
- 06/06/22 Morgan Stanley
- Semrush initiated with an Equal Weight at Morgan Stanley
- 05/12/22 KeyBanc
- KeyBanc downgrades Semrush to Sector Weight on relocation, SMB risks/expenses
- 05/12/22 KeyBanc
- Semrush downgraded to Sector Weight from Overweight at KeyBanc
- 05/12/22 Jefferies
- Semrush price target lowered to $10 from $15 at Jefferies
- 06/06/22 Stephens
- Hanover Bancorp initiated with an Overweight at Stephens
- 06/06/22 Piper Sandler
- Hanover Bancorp initiated with an Overweight at Piper Sandler
SLGBF Good Natured Products - 06/06/22 Raymond James
- Good Natured Products downgraded to Market Perform from Outperform at Raymond James
- 12/14/21 National Bank
- Good Natured Products initiated with an Outperform at National Bank
- 11/02/21 Raymond James
- Good Natured Products price target lowered to C$1.50 from C$2 at Raymond James
- 10/29/21 Canaccord
- Good Natured Products price target lowered to C$1.20 from C$1.90 at Canaccord
TPTX Turning Point Therapeutics - 05/10/22
- Turning Point Therapeutics reports Q1 EPS ($1.50), consensus ($1.51)
- 02/28/22
- Turning Point Therapeutics reports Q4 EPS ($1.58), consensus ($1.39)
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
- 04/27/22
- Spotify sees Q2 revenue EUR 2.8B, MAUs 428M
- 04/27/22
- Spotify reports Q1 EPS EUR 0.21 vs. (EUR 0.25) last year
- 02/02/22
- Spotify reports Q4 EPS (EUR0.21) vs (EUR0.66) last year
- 05/10/22
- Semrush sees FY22 revenue $249M-$251M, consensus $244.94M
- 05/10/22
- Semrush sees Q2 revenue $59.5M-$60.5M, consensus $59.03M
- 05/10/22
- Semrush reports Q1 EPS (2c), consensus (3c)
- 02/28/22
- Semrush sees FY22 revenue $245M-$247M, consensus $237.4M
RVMD Revolution Medicines - 05/09/22
- Revolution Medicines sees FY22 GAAP net loss $260M-$290M
- 05/09/22
- Revolution Medicines reports Q1 EPS (78c), consensus (77c)
- 02/28/22
- Revolution Medicines reports Q3 EPS (71c), consensus (64c)
- 05/10/22
- PMV Pharmaceuticals reports Q1 EPS (41c), consensus (40c)
- 03/01/22
- PMV Pharmaceuticals reports 2021 EPS ($1.28), consensus ($1.22)
- 06/02/22
- Lululemon raises FY22 EPS view to $9.35-$9.50 from $9.15-$9.35, consensus $9.28
- 06/02/22
- Lululemon sees Q2 EPS $1.89-$1.94, consensus $1.77
- 06/02/22
- Lululemon reports Q1 EPS $1.48, consensus $1.43
- 03/03/22
- Kroger sees FY22 adjusted EPS $3.75-$3.85, consensus $3.45
- 03/03/22
- Kroger reports Q4 adjusted EPS 91c, consensus 74c
- 03/02/22
- Notable companies reporting before tomorrow's open
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 05/09/22
- Notable companies reporting after market close
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- 05/10/22
- L.B. Foster reports Q1 EPS (15c), consensus (2c)
- 03/01/22
- L.B. Foster reports Q4 EPS (3c), two estimates 19c
- 05/03/22
- Edison International backs FY22 EPS view of $4.40-$4.70, consensus $4.51
- 05/03/22
- Edison International reports Q1 EPS $1.07, consensus 79c
- 02/24/22
- Edison International sees FY22 core EPS $4.40-$4.70, consensus $4.56
- 02/24/22
- Edison International reports Q4 core EPS $1.16, consensus $1.04
- 05/09/22
- Dun & Bradstreet sees FY22 adjusted EPS $1.13-$1.20, consensus $1.15
- 05/09/22
- Dun & Bradstreet reports Q1 adjusted EPS 24c, consensus 23c
- 02/16/22
- Dun & Bradstreet reports Q4 EPS (3c) consensus 3c
- 05/05/22
- DoorDash reports Q1 EPS (48c), consensus (41c)
- 05/05/22
- Notable companies reporting after market close
- 02/16/22
- DoorDash reports Q4 EPS (45c), consensus (25c)
- 02/16/22
- Notable companies reporting after market close
- $164.16 /
+2.095 (+1.29%) - 06/02/22
- CrowdStrike raises FY23 EPS view to $1.18-$1.22 from $1.03-$1.13
- 06/02/22
- CrowdStrike sees Q2 adjusted EPS 27c-28c, consensus 24c
- 06/02/22
- CrowdStrike reports Q1 adjusted EPS 31c, consensus 23c
- 06/02/22
- Notable companies reporting after market close
- 04/29/22
- Bristol-Myers lowers FY22 adjusted EPS view to $7.44-$7.74 from $7.65-$7.95
- 04/29/22
- Bristol-Myers reports Q1 EPS $1.96, consensus $1.91
- 04/28/22
- Notable companies reporting before tomorrow's open
- 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 04/22/22
- American Express reports Q1 EPS $2.73, consensus $2.44
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
- 01/25/22
- American Express sees FY22 EPS $9.25-$9.65, consensus $9.67
- 01/25/22
- American Express reports Q4 EPS $2.18, consensus $1.87
- 05/12/22
- Aurora Cannabis reports Q3 revenue C$50.43M vs. C$55.16M a year ago
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
|
Downgrade
|
H.C. Wainwright analyst… H.C. Wainwright analyst Robert Burns downgraded Turning Point Therapeutics (TPTX) to Neutral from Buy with a price target of $76, down from $161, after the company entered into a definitive merger agreement with Bristol-Myers Squibb (BMY). In the wake of this transaction, the analyst points out to investors several other precision oncology companies in his universe that he believes could be acquisition targets for major pharma, including: PMV Pharmaceuticals (PMVP), Springworks Therapeutics (SWTX) and Revolution Medicines (RVMD). ShowHide Related Items >><< TPTX Turning Point Therapeutics - $74.58 /
+40.38 (+118.07%) - 06/03/22
- Turning Point Therapeutics jumps 117% to $74.16 after Bristol-Myers buyout offer
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 05/16/22
- Turning Point Therapeutics appoints Steve Sabus as CCO
SWTX SpringsWorks Therapeutics - 05/26/22
- SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO
- 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
- 12/10/21
- SpringsWorks Therapeutics announces trial collaboration with AbbVie
RVMD Revolution Medicines - 03/24/22
- Revolution Medicines director buys $5.49M in common stock
- 05/26/22
- PMV Pharmaceuticals: Lead program, PC14586 accepted as oral presentation at ASCO
- 04/27/22
- PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO
- 06/03/22
- Bristol-Myers withdraws sBLA for Reblozyl
TPTX Turning Point Therapeutics - $74.58 /
+40.38 (+118.07%) - 06/05/22 BofA
- BofA keeps Buy on Bristol-Myers, raises price target to $80
- 06/03/22 Oppenheimer
- Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
- 06/03/22 Wells Fargo
- Turning Point Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- 06/03/22 Stifel
- Bristol-Myers' offer for Turning Point Therapeutics 'fair,' says Stifel
- 06/03/22 Raymond James
- Raymond James downgrades Bristol-Myers on valuation after Turning Point deal
- 03/02/22 Oppenheimer
- Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
- 03/02/22 Oppenheimer
- PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- 09/22/21 Goldman Sachs
- PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 08/19/21 Oppenheimer
- PMV Pharmaceuticals initiated with a Perform at Oppenheimer
SWTX SpringsWorks Therapeutics - 05/27/22 Wedbush
- SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
- 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
- 03/01/22 H.C. Wainwright
- SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright
- 10/27/21 Wedbush
- Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data
RVMD Revolution Medicines - 05/20/22 BofA
- BofA starts Revolution Medicines at Neutral with $24 price target
- 05/20/22 BofA
- Revolution Medicines initiated with a Neutral at BofA
- 03/01/22 Stifel
- Stifel upgrades Revolution Medicines, sees good entry point after pullback
- 03/01/22 H.C. Wainwright
- Revolution Medicines price target raised to $40 from $38 at H.C. Wainwright
TPTX Turning Point Therapeutics - $74.58 /
+40.38 (+118.07%) - 05/10/22
- Turning Point Therapeutics reports Q1 EPS ($1.50), consensus ($1.51)
- 02/28/22
- Turning Point Therapeutics reports Q4 EPS ($1.58), consensus ($1.39)
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
RVMD Revolution Medicines - 05/09/22
- Revolution Medicines sees FY22 GAAP net loss $260M-$290M
- 05/09/22
- Revolution Medicines reports Q1 EPS (78c), consensus (77c)
- 02/28/22
- Revolution Medicines reports Q3 EPS (71c), consensus (64c)
- 05/10/22
- PMV Pharmaceuticals reports Q1 EPS (41c), consensus (40c)
- 03/01/22
- PMV Pharmaceuticals reports 2021 EPS ($1.28), consensus ($1.22)
- 04/29/22
- Bristol-Myers lowers FY22 adjusted EPS view to $7.44-$7.74 from $7.65-$7.95
- 04/29/22
- Bristol-Myers reports Q1 EPS $1.96, consensus $1.91
- 04/28/22
- Notable companies reporting before tomorrow's open
- 05/19/22
- Wolfpack issues short report on 'significantly overpriced' PMV
- 05/19/22
- Wolfpack Research announces short position in PMV Pharmaceuticals
- 05/28/22
- Buy Bristol-Myers, rally just getting started, Barron's says
TPTX Turning Point Therapeutics - $74.58 /
+40.38 (+118.07%) - 06/03/22
- What You Missed On Wall Street On Friday
- 06/03/22
- What You Missed On Wall Street This Morning
- 06/03/22
- Fly Intel: Pre-market Movers
- 05/20/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
SWTX SpringsWorks Therapeutics - 05/24/22
- What You Missed On Wall Street On Tuesday
- 05/24/22
- What You Missed On Wall Street This Morning
- 05/13/22
- Proven algorithm says sell these stocks now
RVMD Revolution Medicines - 03/28/22
- Fly Insider: GameStop, Agilent among this week's notable insider trades
- 03/01/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 05/27/22
- What You Missed On Wall Street On Friday
- 05/27/22
- What You Missed On Wall Street This Morning
- 05/26/22
- Fly Intel: After-Hours Movers
- 05/12/22
- Fly Intel: Pre-market Movers
- 06/02/22
- Unusually active option classes on open June 2nd
- 02/16/22
- Bristol Myers Squibb call volume above normal and directionally bullish
- 01/10/22
- Early notable gainers among liquid option names on January 10th
- 12/15/21
- Bristol Myers Squibb call volume above normal and directionally bullish
|